Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2015

View Archived Issues

Pfizer synthesizes new Abeta production inhibitors

Selective Nav1.7 inhibitors for the treatment of pain

IncellDx and Claremont to combine technologies for liquid-based biopsy system

JCR Pharma initiates development of ERT using BBB-crossing technology

Nanosyn and LLS update progress of MLL leukemia project

Piramal Enterprises presents BRD4 inhibitors

Sunshine Lake Pharma presents SGLT2 inhibitors

GDF15 may be a superior biomarker for mitochondrial disease diagnosis

Johnson & Johnson recaps highlights of first quarter 2015

Ombitasvir/paritaprevir/ritonavir HCV combination granted priority review in Japan

Avelas starts phase I trial of real-time fluorescent illuminator for breast cancer surgery

Baxter files for approval of BAX-855 in Japan

Isarna Therapeutics initiates first-in-human trial of ISTH-0036

Receptos's ozanimod achieves efficacy endpoints in phase II ulcerative colitis trial

TC-6499 fails to reduce gastric emptying time in diabetic gastroparesis study

Tipelukast receives FDA fast track designation for NASH with fibrosis

Actelion updates on clinical development of S1P1 receptor modulators

Discovery Laboratories advances development of Aerosurf, ceases commercialization of Surfaxin

World Hemophilia Day: Hyperfunctional FIX as a promising tool in hemophilia

Anacor reports boron-containing PDE4 inhibitors

Merck & Co. develops Trk-A inhibitors

FDA grants orphan drug designation to selumetinib for uveal melanoma

Chugai presents anti-protein-C MAbs

Provectus initiates phase III trial of PV-10 in melanoma

Genmab achieves fifth milestone in daratumumab collaboration with Janssen Biotech

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...